Publications
2024
The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline.
Fox, C. P., Chaganti, S., McIlroy, G., Barrington, S. F., Burton, C., Cwynarski, K., . . . Davies, A. J. (2024). The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline.. British journal of haematology, 204(4), 1178-1192. doi:10.1111/bjh.19273
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Duell, J., Abrisqueta, P., Andre, M., Gaidano, G., Gonzales-Barca, E., Jurczak, W., . . . Salles, G. (2024). Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.. Haematologica, 109(2), 553-566. doi:10.3324/haematol.2023.283480
Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohort.
Kirwan, P. D., Hall, V. J., Foulkes, S., Otter, A. D., Munro, K., Sparkes, D., . . . Hopkins, S. (2024). Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohort.. The Lancet regional health. Europe, 36, 100809. doi:10.1016/j.lanepe.2023.100809
Highly Multiplexed and Simultaneous Characterization of Protein and RNA in Single Cells by Flow or Mass Cytometry Platforms Using Proximity Ligation Assay for RNA.
Duckworth, A. D., Slupsky, J. R., & Kalakonda, N. (2024). Highly Multiplexed and Simultaneous Characterization of Protein and RNA in Single Cells by Flow or Mass Cytometry Platforms Using Proximity Ligation Assay for RNA.. Methods in molecular biology (Clifton, N.J.), 2752, 143-165. doi:10.1007/978-1-0716-3621-3_10
2023
Immunomodulatory Effects of Chemo-Immunotherapy ± Idelalisib in Chronic Lymphocytic Leukaemia (CLL)
Lim, Y. J., Duckworth, A., Clarke, K., Oates, M., Gornall, M., Kalakonda, N., . . . Pettitt, A. (2023). Immunomodulatory Effects of Chemo-Immunotherapy ± Idelalisib in Chronic Lymphocytic Leukaemia (CLL). Blood, 142(Supplement 1), 1455. doi:10.1182/blood-2023-185063
Early Warning Surveillance for SARS-CoV-2 Omicron Variants, United Kingdom, November 2021-September 2022.
Foulkes, S., Monk, E. J. M., Sparkes, D., Hettiarachchi, N., Milligan, I. D., Munro, K., . . . SIREN Study Group. (2023). Early Warning Surveillance for SARS-CoV-2 Omicron Variants, United Kingdom, November 2021-September 2022.. Emerging infectious diseases, 29(1), 184-188. doi:10.3201/eid2901.221293
2022
PKCβ Facilitates Leukemogenesis in Chronic Lymphocytic Leukaemia by Promoting Constitutive BCR-Mediated Signalling
Hay, J., Tarafdar, A., Holroyd, A. K., Moka, H. A., Dunn, K. M., Alshayeb, A., . . . Michie, A. M. (2022). PKCβ Facilitates Leukemogenesis in Chronic Lymphocytic Leukaemia by Promoting Constitutive BCR-Mediated Signalling. CANCERS, 14(23). doi:10.3390/cancers14236006
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features
Robbe, P., Ridout, K. E., Vavoulis, D. V., Dreau, H., Kinnersley, B., Denny, N., . . . Schuh, A. (2022). Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features. NATURE GENETICS, 54(11), 1675-+. doi:10.1038/s41588-022-01211-y
COVID-19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta-analysis.
Lim, Y. J., Khan, U., Karpha, I., Ross, A., Saif, M., Remberger, M., . . . Floisand, Y. (2022). COVID-19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta-analysis.. EJHaem, 3(3), 862-872. doi:10.1002/jha2.465
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
Zijlstra, J. M., Follows, G., Casasnovas, R. -O., Vermaat, J. S. P., Kalakonda, N., Choquet, S., . . . Maerevoet, M. (2022). The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study. CANCERS, 14(3). doi:10.3390/cancers14030791
Safety and efficacy of durvalumab with R-CHOP or R<SUP>2</SUP>-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial
Nowakowski, G. S., Willenbacher, W., Greil, R., Larsen, T. S., Patel, K., Jaeger, U., . . . Munoz, J. (2022). Safety and efficacy of durvalumab with R-CHOP or R<SUP>2</SUP>-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. INTERNATIONAL JOURNAL OF HEMATOLOGY, 115(2), 222-232. doi:10.1007/s12185-021-03241-4
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes
Casasnovas, R. -O., Follows, G., Zijlstra, J. M., Vermaat, J. S. P., Kalakonda, N., Choquet, S., . . . Goy, A. (2022). Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 22(1), 24-33. doi:10.1016/j.clml.2021.07.017
Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England
Hounsome, L., Eyre, T. A., Ireland, R., Hodson, A., Walewska, R., Ardeshna, K., . . . Fields, P. A. (2022). Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England. BRITISH JOURNAL OF CANCER, 126(1), 134-143. doi:10.1038/s41416-021-01525-4
Ibrutinib therapy related uveitis: A single-centre case series and literature review
Kalakonda, A. J. M., Jeffers, L., Wells, M., Pettitt, A., Kalakonda, N., Arumainathan, A., . . . Williams, S. (2022). Ibrutinib therapy related uveitis: A single-centre case series and literature review. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 197 (pp. 194). Retrieved from https://www.webofscience.com/
2021
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
Schuster, M., Zijlstra, J., Casasnovas, R. -O., Vermaat, J. S. P., Kalakonda, N., Goy, A., . . . Maerevoet, M. (2021). Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study. Clinical Lymphoma Myeloma and Leukemia. doi:10.1016/j.clml.2021.12.016
Role of MYC and BCL2 expression in a cohort of 43 patients with DLBCL: a retrospective study
Khan, U. T., Kelly, M., Dodd, J., Fergiani, S., Hammer, B., Smith, J., . . . Menon, G. (2021). Role of MYC and BCL2 expression in a cohort of 43 patients with DLBCL: a retrospective study. JOURNAL OF CLINICAL PATHOLOGY, 74(12), 816-818. doi:10.1136/jclinpath-2020-207121
Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells
Linley, A. J., Karydis, L. I., Mondru, A. K., D'Avola, A., Al Shmrany, H., Cicconi, S., . . . Slupsky, J. R. (2021). Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells. CLINICAL CANCER RESEARCH, 27(20), 5647-5659. doi:10.1158/1078-0432.CCR-21-0161
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
Duell, J., Maddocks, K. J., Gonzalez-Barca, E., Jurczak, W., Liberati, A. M., de Vos, S., . . . Salles, G. (2021). Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. In HAEMATOLOGICA Vol. 106 (pp. 2417-2426). doi:10.3324/haematol.2020.275958
Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (MOR208) Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Salles, G., Duell, J., Gonzalez-Barca, E., Jurczak, W., Liberati, A. M., de Vos, S., . . . Maddocks, K. J. (2020). Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (MOR208) Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 20 (pp. S267-S268). Retrieved from https://www.webofscience.com/
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Maerevoet, M., Zijlstra, J. M., Follows, G., Casasnovas, R. -O., Vermaat, J. S. P., Kalakonda, N., . . . Canales, M. (2021). Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. JOURNAL OF HEMATOLOGY & ONCOLOGY, 14(1). doi:10.1186/s13045-021-01122-1
COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study
Hall, V. J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., . . . Hopkins, S. (2021). COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. LANCET, 397(10286), 1725-1735. doi:10.1016/S0140-6736(21)00790-X
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)
Hall, V. J., Foulkes, S., Charlett, A., Atti, A., Monk, E. J. M., Simmons, R., . . . Hopkins, S. (2021). SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). LANCET, 397(10283), 1459-1469. doi:10.1016/S0140-6736(21)00675-9
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
Shah, J., Shacham, S., Kauffman, M., Daniele, P., Tomaras, D., Tremblay, G., . . . Canales Albendea, M. A. (2021). Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. FUTURE ONCOLOGY, 17(11), 1295-1310. doi:10.2217/fon-2020-0946
Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.
Bhogal, T., Khan, U. T., Lee, R., Stockdale, A., Hesford, C., Potti-Dhananjaya, V., . . . Palmieri, C. (2021). Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.. Leukemia & lymphoma, 1-16. doi:10.1080/10428194.2021.1876865
2020
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.
Pettitt, A. R., Jackson, R., Cicconi, S., Polydoros, F., Yap, C., Dodd, J., . . . Hillmen, P. (2020). Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.. Haematologica, 105(12), 2868-2871. doi:10.3324/haematol.2019.230805
Selinexor for relapsed or refractory diffuse large B-cell lymphoma: examining the artifact Reply
Kalakonda, N., Kauffman, M., & Shah, J. (2020). Selinexor for relapsed or refractory diffuse large B-cell lymphoma: examining the artifact Reply. LANCET HAEMATOLOGY, 7(10), E707-E708. Retrieved from https://www.webofscience.com/
Selinexor in patients with relapsed or refractory diffuse large B -cell lymphoma (SADAL): a single -arm, multinational, multicentre, open -label, phase 2 trial
Kalakonda, N., Maerevoet, M., Cavallo, F., Follows, G., Goy, A., Vermaat, J. S. P., . . . Canales, M. A. (2020). Selinexor in patients with relapsed or refractory diffuse large B -cell lymphoma (SADAL): a single -arm, multinational, multicentre, open -label, phase 2 trial. The Lancet Haematology, 7(7), E509-E522. doi:10.1016/S2352-3026(20)30120-4
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
Salles, G., Duell, J., Gonzalez Barca, E., Tournilhac, O., Jurczak, W., Liberati, A. M., . . . Maddocks, K. (2020). Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. The Lancet Oncology, 21(7), 978-988. doi:10.1016/S1470-2045(20)30225-4
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial
Pettitt, A. R., Jackson, R., Cicconi, S., Polydoros, F., Yap, C., Dodd, J., . . . Hillmen, P. (2020). Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial. HAEMATOLOGICA, 105(12), 2868-2871. doi:10.3324/haematol.2019.230805
Deep phenotypic analysis of mutated and unmutated CLL cells by mass cytometry
Jawad, M., Sophie, A., Duckworth, A., Karpha, I., Bithell, J., Oates, M., . . . Slupsky, J. (2020). Deep phenotypic analysis of mutated and unmutated CLL cells by mass cytometry. In LEUKEMIA & LYMPHOMA Vol. 61 (pp. 177-179). Retrieved from https://www.webofscience.com/
HEALTH UTILITY IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (RR-DLBCL) PATIENTS - RESULTS OF A PHASE II TRIAL WITH ORAL SELINEXOR
Casasnovas, R. O., Daniele, P., Tremblay, G., Maerevoet, M., Zijlstra, J., Follows, G., . . . Canales Albendea, M. A. (2020). HEALTH UTILITY IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (RR-DLBCL) PATIENTS - RESULTS OF A PHASE II TRIAL WITH ORAL SELINEXOR. In VALUE IN HEALTH Vol. 23 (pp. S479-S480). Retrieved from https://www.webofscience.com/
Highly multiplexed and simultaneous analysis of protein and RNA expression in chronic lymphocytic leukaemia using PLAYR and mass cytometry
Duckworth, A., Sykorova, M., Yasin, F., Slupsky, J., & Kalakonda, N. (2020). Highly multiplexed and simultaneous analysis of protein and RNA expression in chronic lymphocytic leukaemia using PLAYR and mass cytometry. In LEUKEMIA & LYMPHOMA Vol. 61 (pp. 228-229). Retrieved from https://www.webofscience.com/
Mass cytometry analysis of B cell receptor signaling in normal B and chronic lymphocytic leukaemia cells in peripheral blood.
Yasin, F., Duckworth, A., Till, K., Pettitt, A., Lin, K., Kalakonda, N., & Slupsky, J. (2020). Mass cytometry analysis of B cell receptor signaling in normal B and chronic lymphocytic leukaemia cells in peripheral blood.. In LEUKEMIA & LYMPHOMA Vol. 61 (pp. 185-187). Retrieved from https://www.webofscience.com/
Using signal-omics to fingerprint the impact of antigen engagement and therapy on BCR activation in CLL.
Linley, A., Kalakonda, N., Forconi, F., Pettitt, A., MacEwan, D., Packham, G., . . . Slupsky, J. (2020). Using signal-omics to fingerprint the impact of antigen engagement and therapy on BCR activation in CLL.. In LEUKEMIA & LYMPHOMA Vol. 61 (pp. 1-2). Retrieved from https://www.webofscience.com/
2019
Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study
Cavallo, F., Follows, G. A., Goy, A., Vermaat, J., Casasnovas, R. -O., Lavee, O., . . . Kalakonda, N. (2019). Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study. In BLOOD Vol. 134. doi:10.1182/blood-2019-122900
A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Kalakonda, N., Cavallo, F., Follows, G., Goy, A., Vermaat, J. S. P., Casasnovas, O., . . . Canales, M. (2019). A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 19 (pp. S248-S249). doi:10.1016/j.clml.2019.07.153
POTENTIAL THERAPEUTIC ADVANTAGE FOR DUVELISIB IN MANTLE CELL LYMPHOMA: PI3Kδ AND OVEREXPRESSED PI3Kγ IN LYMPHOMA CELLS HAVE SPECIALIZED FUNCTIONAL ROLES
Till, K. J., Gallardo Zapata, J., Marks, T., Weaver, D. T., Pachter, J. A., Abdullah, M., . . . Slupsky, J. R. (2019). POTENTIAL THERAPEUTIC ADVANTAGE FOR DUVELISIB IN MANTLE CELL LYMPHOMA: PI3Kδ AND OVEREXPRESSED PI3Kγ IN LYMPHOMA CELLS HAVE SPECIALIZED FUNCTIONAL ROLES. In Hematological Oncology Vol. 37 (pp. 511-512). Wiley. doi:10.1002/hon.194_2631
Multiplexed profiling of RNA and protein expression signatures in individual cells using flow or mass cytometry
Duckworth, A. D., Gherardini, P. F., Sykorova, M., Yasin, F., Nolan, G. P., Slupsky, J. R., & Kalakonda, N. (2019). Multiplexed profiling of RNA and protein expression signatures in individual cells using flow or mass cytometry. Nature Protocols, 14(03), 901-920. doi:10.1038/s41596-018-0120-8
Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R<SUP>2</SUP>-CHOP in subjects with previously untreated, high-risk DLBCL.
Nowakowski, G. S., Willenbacher, W., Greil, R., Larsen, T. S., Patel, K., Jager, U., . . . Munoz, J. (2019). Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R<SUP>2</SUP>-CHOP in subjects with previously untreated, high-risk DLBCL.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37. Retrieved from https://www.webofscience.com/
Update of the single-arm phase II L-MIND study of MOR208+lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): Response rates in patient subgroups with poor prognosis.
Maddocks, K. J., Duell, J., Barca, E. G., Jurczak, W., Liberati, A. M., Nagy, Z., . . . Salles, G. A. (2019). Update of the single-arm phase II L-MIND study of MOR208+lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): Response rates in patient subgroups with poor prognosis.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37. Retrieved from https://www.webofscience.com/
2018
Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non GCB Subtypes: The Phase 2b Sadal Study
Maerevoet, M., Vermaat, J., Canales, M. A., Casasnovas, R. -O., Van den Neste, E., Goy, A., . . . Zijlstra, J. M. (2018). Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non GCB Subtypes: The Phase 2b Sadal Study. In BLOOD Vol. 132. doi:10.1182/blood-2018-99-116868
Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind
Salles, G. A., Duell, J., Gonzalez-Barca, E., Jurczak, W., Liberati, A. M., Nagy, Z., . . . Maddocks, K. J. (2018). Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind. In BLOOD Vol. 132. doi:10.1182/blood-2018-99-113399
Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial
Anderson, R. A., Remedios, R., Kirkwood, A. A., Patrick, P., Stevens, L., Clifton-Hadley, L., . . . Johnson, P. W. M. (2018). Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial. The Lancet. Oncology, 19(10), 1328-1337. doi:10.1016/S1470-2045(18)30500-X
Perspectives of patients with haematological cancer on how clinicians meet their information needs: "Managing" information versus "giving" it
Atherton, K., Young, B., Kalakonda, N., & Salmon, P. (2018). Perspectives of patients with haematological cancer on how clinicians meet their information needs: "Managing" information versus "giving" it. PSYCHO-ONCOLOGY, 27(07), 1719-1726. doi:10.1002/pon.4714
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial
Gleeson, M., Peckitt, C., To, Y. M., Edwards, L., Oates, J., Wotherspoon, A., . . . Cunningham, D. (2018). CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. LANCET HAEMATOLOGY, 5(5), E190-E200. doi:10.1016/S2352-3026(18)30039-5
2017
Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome
Till, K. J., Allen, J. C., Talab, F., Lin, K., Allsup, D., Cawkwell, L., . . . Slupsky, J. R. (2017). Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome. SCIENTIFIC REPORTS, 7. doi:10.1038/s41598-017-17021-w
Transcriptional mechanism of vascular endothelial growth factor-induced expression of protein kinase CβII in chronic lymphocytic leukaemia cells
Al-Sanabra, O., Duckworth, A. D., Glenn, M. A., Brown, B. R., Angelillo, P., Lee, K., . . . Slupsky, J. R. (2017). Transcriptional mechanism of vascular endothelial growth factor-induced expression of protein kinase CβII in chronic lymphocytic leukaemia cells. Scientific Reports, 7. doi:10.1038/srep43228
Investigating the CLL kinome to understand BCR signaling dynamics and the influence of kinase inhibitors
Slupsky, J., Prior, I., MacEwan, D., Wilson, L., Linley, A., & Kalakonda, N. (2017). Investigating the CLL kinome to understand BCR signaling dynamics and the influence of kinase inhibitors. In LEUKEMIA & LYMPHOMA Vol. 58 (pp. 3-4). Retrieved from https://www.webofscience.com/
2016
Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain
Iyer, D., Vartak, S. V., Mishra, A., Goldsmith, G., Kumar, S., Srivastava, M., . . . Raghavan, S. C. (2016). Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain. The Federation of European Biochemical Societies (FEBS) Journal, 283(18), 3408-3437. doi:10.1111/febs.13815
2015
CLL Exosomes Modulate the Transcriptome and Behaviour of Recipient Stromal Cells and Are Selectively Enriched in miR-202-3p
Farahani, M., Rubbi, C., Liu, L., Slupsky, J. R., & Kalakonda, N. (2015). CLL Exosomes Modulate the Transcriptome and Behaviour of Recipient Stromal Cells and Are Selectively Enriched in miR-202-3p. PLOS ONE, 10(10). doi:10.1371/journal.pone.0141429
2014
CC-122 Has Robust Anti-Proliferative Activity in a Primary Chronic Lymphocytic Leukemia (CLL) Co-Culture Model and Is Superior to Lenalidomide
Blocksidge, J., Glenn, M., Gandhi, A. K., Klippel, A., Pourdehnad, M., Chopra, R., & Kalakonda, N. (2014). CC-122 Has Robust Anti-Proliferative Activity in a Primary Chronic Lymphocytic Leukemia (CLL) Co-Culture Model and Is Superior to Lenalidomide. BLOOD, 124(21). doi:10.1182/blood.V124.21.4682.4682
Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia
Lin, K., Farahani, M., Yang, Y., Johnson, G. G., Oates, M., Atherton, M., . . . Pettitt, A. R. (2014). Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 167(3), 346-355. doi:10.1111/bjh.13043
Variable induction of PRDM1 and differentiation in chronic lymphocytic leukemia is associated with anergy.
Duckworth, A., Glenn, M., Slupsky, J. R., Packham, G., & Kalakonda, N. (2014). Variable induction of PRDM1 and differentiation in chronic lymphocytic leukemia is associated with anergy.. Blood, 123(21), 3277-3285. doi:10.1182/blood-2013-11-539049
CLL DERIVED EXOSOMES ENCAPSULATE SPECIFIC MICRORNAS AND INFLUENCE STROMAL CELL BEHAVIOUR
Farahani, M., Angelillo, P., Kelly, M., Liu, L., Rubbi, C., & Kalakonda, N. (2014). CLL DERIVED EXOSOMES ENCAPSULATE SPECIFIC MICRORNAS AND INFLUENCE STROMAL CELL BEHAVIOUR. In HAEMATOLOGICA Vol. 99 (pp. 40-41). Retrieved from https://www.webofscience.com/
COMPARISON OF GEMCITABINE <i>VS</i>. NON-GEMCITABINE BASED SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY AGGRESSIVE LYMPHOMA
Taylor, D., Angelillo, P., Ward, C., Collins, D., Salim, R., Pettitt, A., . . . Kalakonda, N. (2014). COMPARISON OF GEMCITABINE <i>VS</i>. NON-GEMCITABINE BASED SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY AGGRESSIVE LYMPHOMA. In HAEMATOLOGICA Vol. 99 (pp. 701). Retrieved from https://www.webofscience.com/
2013
Differential induction of PRDM1 in CLL cells is linked to the antigenic stimulus and stability of anergy
Duckworth, A., Glenn, M., Slupsky, J. R., Packham, G., & Kalakonda, N. (2013). Differential induction of PRDM1 in CLL cells is linked to the antigenic stimulus and stability of anergy.
High expression of <i>TP53</i> mRNA is associated with allelic loss of 13q14 and short survival in chronic lymphocytic leukaemia
Lin, K., Johnson, G. G., Farahani, M., Oates, M., Atherton, M., Douglas, A., . . . Pettitt, A. R. (2013). High expression of <i>TP53</i> mRNA is associated with allelic loss of 13q14 and short survival in chronic lymphocytic leukaemia. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 161 (pp. 43-44). Retrieved from https://www.webofscience.com/
MicroRNAs encapsulated by exosomes from CLL cells are critical for modulation of the tumour microenvironment
Farahani, M., Bee, A., Rubbi, C., & Kalakonda, N. (2013). MicroRNAs encapsulated by exosomes from CLL cells are critical for modulation of the tumour microenvironment.
Regulation and functional importance of Integrin expression in CLL cells
Glenn, M., Duckworth, A., Blocksidge, J., Till, K., Pettitt, A. R., Slupsky, J. R., & Kalakonda, N. (2013). Regulation and functional importance of Integrin expression in CLL cells.
SF3B1 mutational status impacts on LEDGF alternative splicing and disease behaviour in Chronic Lymphocytic Leukemia
Blocksidge, J., Glenn, M., Bee, A., Duckworth, A., Johnson, G., Pettitt, A. R., . . . Kalakonda, N. (2013). SF3B1 mutational status impacts on LEDGF alternative splicing and disease behaviour in Chronic Lymphocytic Leukemia.
The transcription factor Sp1 regulates PKCβ expression in chronic lymphocytic leukaemia cells
Al-Sanabra, O., Glenn, M., Kalakonda, N., & Slupsky, J. R. (2013). The transcription factor Sp1 regulates PKCβ expression in chronic lymphocytic leukaemia cells.
2012
DNA Methylation Abnormalities in Mature B-cell Lymphoid Neoplasms
Glenn, M., Duckworth, A., & Kalakonda, N. (2012). DNA Methylation Abnormalities in Mature B-cell Lymphoid Neoplasms. CML - Leukemia & Lymphoma, 20(4), 109-118.
DNA Methylation Abnormalities in Mature B-cell Lymphoid Neoplasms
Glenn, M., Duckworth, A., & Kalakonda, N. (2012). DNA Methylation Abnormalities in Mature B-cell Lymphoid Neoplasms. Unknown Journal, 4(20), 109-118.
2011
Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p
Arumainathan, A., Kalakonda, N., & Pettitt, A. R. (2011). Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p. EUROPEAN JOURNAL OF HAEMATOLOGY, 87(4), 372-375. doi:10.1111/j.1600-0609.2011.01667.x
Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.
Arumainathan, A., Kalakonda, N., & Pettitt, A. R. (2011). Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.. Eur J Haematol., 87(4), 372-375.
2008
Histone H4 lysine 20 monomethylation promotes transcriptional repression by L3MBTL1
Kalakonda, N., Fischle, W., Boccuni, P., Gurvich, N., Hoya-Arias, R., Zhao, X., . . . Nimer, S. D. (2008). Histone H4 lysine 20 monomethylation promotes transcriptional repression by L3MBTL1. ONCOGENE, 27(31), 4293-4304. doi:10.1038/onc.2008.67
2007
L3MBTL1, a histone-methylation-dependent chromatin lock
Trojer, P., Li, G., Sims, R. J. I. I. I., Vaquero, A., Kalakonda, N., Boccuni, P., . . . Reinberg, D. (2007). L3MBTL1, a histone-methylation-dependent chromatin lock. CELL, 129(5), 915-928. doi:10.1016/j.cell.2007.03.048
2005
Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO):: possible mechanisms to explain ATO resistance <i>in vivo</i>
Zhou, P., Kalakonda, N., & Comenzo, R. L. (2005). Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO):: possible mechanisms to explain ATO resistance <i>in vivo</i>. BRITISH JOURNAL OF HAEMATOLOGY, 128(5), 636-644. doi:10.1111/j.1365-2141.2005.05369.x
Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial
Gupta, S., Zhou, P., Hassoun, H., Kewalramani, T., Reich, L., Costello, S., . . . Comenzo, R. L. (2005). Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial. BONE MARROW TRANSPLANTATION, 35(5), 441-447. doi:10.1038/sj.bmt.1704779
2004
Structural integrity and expression of the <i>L3MBTL</i> gene in normal and malignant hematopoietic cells
MacGrogan, D., Kalakonda, N., Alvarez, S., Scandura, J. M., Boccuni, P., Johansson, B., & Nimer, S. D. (2004). Structural integrity and expression of the <i>L3MBTL</i> gene in normal and malignant hematopoietic cells. GENES CHROMOSOMES & CANCER, 41(3), 203-213. doi:10.1002/gcc.20087
Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association
Cohen, A. D., Zhou, P., Xiao, Q., Fleisher, M., Kalakonda, N., Akhurst, T., . . . Comenzo, R. L. (2004). Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association. BRITISH JOURNAL OF HAEMATOLOGY, 124(3), 309-314. doi:10.1046/j.1365-2141.2003.04779.x
Oncolytic herpes simplex virus-1 mutant expressing green fluorescent protein can detect and treat peritoneal cancer
Stanziale, S. F., Stiles, B. M., Bhargava, A., Kerns, S. A., Kalakonda, N., & Fong, Y. M. (2004). Oncolytic herpes simplex virus-1 mutant expressing green fluorescent protein can detect and treat peritoneal cancer. HUMAN GENE THERAPY, 15(6), 609-618. doi:10.1089/104303404323142051
2003
Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma
Hedvat, C. V., Comenzo, R. L., Teruya-Feldstein, J., Olshen, A. B., Ely, S. A., Osman, K., . . . Nimer, S. D. (2003). Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. BRITISH JOURNAL OF HAEMATOLOGY, 122(5), 728-744. doi:10.1046/j.1365-2141.2003.04481.x
Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination
Zhou, P., Zhang, Y., Martinez, C., Kalakonda, N., Nimer, S. D., & Comenzo, R. L. (2003). Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination. BLOOD, 102(2), 477-479. doi:10.1182/blood-2002-12-3674
2002
Activating Ras mutations in patients with plasma-cell disorders: a reappraisal.
Bezieau, S., Avet-Loiseau, H., Moisan, J. -P., & Bataille, R. (2002). Activating Ras mutations in patients with plasma-cell disorders: a reappraisal.. Blood, 100(3), 1101-1102. doi:10.1182/blood-2002-03-0795
Activating Ras mutations in multiple myeloma
Norton, J. D., Rothwell, D. G., & Kalakonda, N. (2002). Activating Ras mutations in multiple myeloma. BLOOD, 100(3), 1103. Retrieved from https://www.webofscience.com/
2001
Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation
Kalakonda, N., Rothwell, D. G., Scarffe, J. H., & Norton, J. D. (2001). Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. BLOOD, 98(5), 1555-1560. doi:10.1182/blood.V98.5.1555
Timing of the appearance of multipotential and committed haemopoietic progenitors in peripheral blood after mobilization in patients with lymphoma
Hepburn, M. D., Nagesh, K., Heppleston, A. D., Cachia, P. G., & Pippard, M. J. (2001). Timing of the appearance of multipotential and committed haemopoietic progenitors in peripheral blood after mobilization in patients with lymphoma. CLINICAL AND LABORATORY HAEMATOLOGY, 23(2), 119-124. doi:10.1046/j.1365-2257.2001.00379.x
2000
Tumour markers formonitoreng minimal residual disease in multiple myeloma
Rothwell, D. G., Kalakonda, N., Norton, J. D., Hawkins, R. E., & Chopra, R. (2000). Tumour markers formonitoreng minimal residual disease in multiple myeloma. Blood, 96(11 PART I).
Immunogenicity of vaccination against influenza, <i>Streptococcus</i> <i>pneumoniae</i> and <i>Haemophilus</i> <i>influenzae</i> type B in patients with multiple myeloma
Robertson, J. D., Nagesh, K., Jowitt, S. N., Dougal, M., Anderson, H., Mutton, K., . . . Scarffe, J. H. (2000). Immunogenicity of vaccination against influenza, <i>Streptococcus</i> <i>pneumoniae</i> and <i>Haemophilus</i> <i>influenzae</i> type B in patients with multiple myeloma. BRITISH JOURNAL OF CANCER, 82(7), 1261-1265. doi:10.1054/bjoc.1999.1088
1999
Content of long-term culture-initiating cells, clonogenic progenitors and CD34<SUP>+</SUP> cells in apheresis harvests of normal donors for allogeneic transplantation, and in patients with acute myeloid leukaemia or multiple myeloma
Kasper, C., Ryder, W. D. J., Dürig, J., Nagesh, K., Scarffe, J. H., Beelen, D. W., . . . Testa, N. G. (1999). Content of long-term culture-initiating cells, clonogenic progenitors and CD34<SUP>+</SUP> cells in apheresis harvests of normal donors for allogeneic transplantation, and in patients with acute myeloid leukaemia or multiple myeloma. BRITISH JOURNAL OF HAEMATOLOGY, 104(2), 374-381. doi:10.1046/j.1365-2141.1999.01152.x
1996
Oncology: Current trials in acute leukaemia
Nagesh, K. (1996). Oncology: Current trials in acute leukaemia. British Journal of Hospital Medicine, 56(10), 535-536.
Current trials in acute leukaemia
Nagesh, K., Jowitt, S. N., & Scarffe, J. H. (1996). Current trials in acute leukaemia. BRITISH JOURNAL OF HOSPITAL MEDICINE, 56(10), 532-536. Retrieved from https://www.webofscience.com/
Recurrent septicaemia in a neutropenic patient with typhlitis
Sadullah, S., Nagesh, K., Johnston, D., McCullough, J. B., Murray, F., & Cachia, P. G. (1996). Recurrent septicaemia in a neutropenic patient with typhlitis. CLINICAL AND LABORATORY HAEMATOLOGY, 18(3), 215-217. doi:10.1046/j.1365-2257.1996.00160.x